LSL Pharma Group Inc.
LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. The company offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, and natural health … Read more
LSL Pharma Group Inc. (LSL) - Total Assets
Latest total assets as of September 2025: CA$60.19 Million CAD
Based on the latest financial reports, LSL Pharma Group Inc. (LSL) holds total assets worth CA$60.19 Million CAD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LSL Pharma Group Inc. - Total Assets Trend (2020–2024)
This chart illustrates how LSL Pharma Group Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
LSL Pharma Group Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
LSL Pharma Group Inc.'s total assets of CA$60.19 Million consist of 28.7% current assets and 71.3% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0.6% |
| Accounts Receivable | CA$4.80 Million | 9.0% |
| Inventory | CA$9.12 Million | 17.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$13.27 Million | 24.8% |
| Goodwill | CA$157.00K | 0.3% |
Asset Composition Trend (2020–2024)
This chart illustrates how LSL Pharma Group Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LSL Pharma Group Inc.'s current assets represent 28.7% of total assets in 2024, an increase from 16.5% in 2020.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2024, down from 1.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, a decrease from 41.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 24.8% of total assets.
LSL Pharma Group Inc. Competitors by Total Assets
Key competitors of LSL Pharma Group Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
LSL Pharma Group Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - LSL Pharma Group Inc. generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, LSL Pharma Group Inc. generates $6.20 in net profit.
LSL Pharma Group Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.53 | 1.17 | 0.65 |
| Quick Ratio | 0.54 | 0.50 | 0.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$7.12 Million | CA$ 1.41 Million | CA$ -3.68 Million |
LSL Pharma Group Inc. - Advanced Valuation Insights
This section examines the relationship between LSL Pharma Group Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | 73.2% |
| Total Assets | CA$53.51 Million |
| Market Capitalization | $24.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values LSL Pharma Group Inc.'s assets below their book value (0.45 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: LSL Pharma Group Inc.'s assets grew by 73.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for LSL Pharma Group Inc. (2020–2024)
The table below shows the annual total assets of LSL Pharma Group Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$53.51 Million | +73.17% |
| 2023-12-31 | CA$30.90 Million | +13.14% |
| 2022-12-31 | CA$27.31 Million | -5.92% |
| 2021-12-31 | CA$29.03 Million | +22.04% |
| 2020-12-31 | CA$23.79 Million | -- |